CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis

被引:41
|
作者
Glatz, Jan F. C. [1 ,2 ]
Nabben, Miranda [1 ,2 ,3 ]
Luiken, Joost J. F. P. [1 ,2 ]
机构
[1] Maastricht Univ, Dept Genet & Cell Biol, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[2] Maastricht Univ Med Ctr, Dept Clin Genet, Maastricht, Netherlands
[3] Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands
关键词
cardiac function; cardiomyopathy; cellular lipid metabolism; cluster of differentiation 36; INSULIN-RESISTANCE; V-ATPASE; CONTRACTILE DYSFUNCTION; LIPID-ACCUMULATION; CANCER-CELLS; METABOLISM; INHIBITION; MEMBRANE; CALCIUM; DISEASE;
D O I
10.1097/MOL.0000000000000819
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review Transmembrane glycoprotein cluster of differentiation 36 (CD36) is a scavenger receptor class B protein (SR-B2) that serves various functions in lipid metabolism and signaling, in particular facilitating the cellular uptake of long-chain fatty acids. Recent studies have disclosed CD36 to play a prominent regulatory role in cellular fatty acid metabolism in both health and disease. Recent findings The rate of cellular fatty acid uptake is short-term (i.e., minutes) regulated by the subcellular recycling of CD36 between endosomes and the plasma membrane. This recycling is governed by the activity of vacuolar-type H+-ATPase (v-ATPase) in the endosomal membrane via assembly and disassembly of two subcomplexes. The latter process is being influenced by metabolic substrates including fatty acids, glucose and specific amino acids, together resulting in a dynamic interplay to modify cellular substrate preference and uptake rates. Moreover, in cases of metabolic disease v-ATPase activity was found to be affected while interventions aimed at normalizing v-ATPase functioning had therapeutic potential. The emerging central role of CD36 in cellular lipid homeostasis and recently obtained molecular insight in the interplay among metabolic substrates indicate the applicability of CD36 as target for metabolic modulation therapy in disease. Experimental studies already have shown the feasibility of this approach.
引用
收藏
页码:103 / 111
页数:9
相关论文
共 50 条
  • [31] A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice
    Gauvin, Jade
    Fregeau, Genevieve
    Elimam, Hanan
    Menard, Liliane
    Huynh, David
    Le, Catherine
    Ahsanullah, Ahsanullah
    Lubell, William D.
    Ong, Huy
    Marleau, Sylvie
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [32] Dietary fatty acid pattern and preferences are not associated with fatty acid transporter CD36 in diabetic patients
    Sakioglu, E. M.
    Kisa, U.
    Durmaz, S. Arikan
    Unal, R. Nergiz
    FEBS JOURNAL, 2016, 283 : 145 - 145
  • [33] The role of fatty acid translocase (FAT/CD36) in acylethanolamides (OEA) mediated fatty acid transport
    Chen, M
    Yang, YK
    Georgeson, K
    Harmon, C
    OBESITY RESEARCH, 2005, 13 : A44 - A44
  • [34] Heart mitochondrial fatty acid oxidation is not affected by deletion of the fatty acid transporter CD36/FAT
    Kerner, Janos
    Febbraio, Maria
    Hoppel, Charles
    FASEB JOURNAL, 2011, 25
  • [35] Association of a polymorphism in the fatty acid transporter CD36 with the prevalence of type 2 diabetes mellitus
    Corpeleijn, E
    van der Kallen, C
    Magagnin, M
    Kruijshoop, M
    de Bruin, T
    Blaak, EE
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S105 - S105
  • [36] Distinct mechanisms for OxLDL uptake and cellular trafficking by class B scavenger receptors CD36 and SR-BI
    Sun, Bing
    Boyanovsky, Boris B.
    Connelly, Margery A.
    Shridas, Preetha
    van der Westhuyzen, Deneys R.
    Webb, Nancy R.
    JOURNAL OF LIPID RESEARCH, 2007, 48 (12) : 2560 - 2570
  • [37] Distinct mechanisms for oxLDL uptake and cellular trafficking by class B scavenger receptors SR-BI and CD36
    Sun, B
    van der Westhuyzen, DR
    Webb, NR
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : E66 - E66
  • [38] Human pancreatic islets express the fatty acid translocase (FAT/CD36)
    Noushmehr, H
    Farilla, L
    Abumrad, N
    Harlan, D
    Wawrowsky, K
    Perfetti, R
    DIABETES, 2003, 52 : A552 - A552
  • [39] CD36 genotype and long-chain fatty acid uptake in the heart
    Kintaka, T
    Tanaka, T
    Imai, M
    Adachi, I
    Narabayashi, I
    Kitaura, Y
    CIRCULATION JOURNAL, 2002, 66 (09) : 819 - 825
  • [40] Regulation of AMPK Activaticin by CD36 Links Fatty Acid Uptake to β-Oxidation
    Samovski, Dmitri
    Sun, Jingyu
    Pietka, Terri
    Gross, Richard W.
    Eckel, Robert H.
    Su, Xiong
    Stahl, Philip D.
    Abumrad, Nada A.
    DIABETES, 2015, 64 (02) : 353 - 359